image
Healthcare - Drug Manufacturers - General - NYSE - UK
$ 38.045
1.21 %
$ 77.6 B
Market Cap
24.08
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one GSK stock under the worst case scenario is HIDDEN Compared to the current market price of 38 USD, GSK plc is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one GSK stock under the base case scenario is HIDDEN Compared to the current market price of 38 USD, GSK plc is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one GSK stock under the best case scenario is HIDDEN Compared to the current market price of 38 USD, GSK plc is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
30.3 B REVENUE
3.42%
6.74 B OPERATING INCOME
4.85%
4.93 B NET INCOME
0.14%
6.77 B OPERATING CASH FLOW
-8.58%
-1.6 B INVESTING CASH FLOW
81.82%
-5.64 B FINANCING CASH FLOW
-685.42%
8.01 B REVENUE
1.62%
189 M OPERATING INCOME
-90.48%
-58 M NET INCOME
-4.94%
2.15 B OPERATING CASH FLOW
144.22%
-731 M INVESTING CASH FLOW
-100.00%
-1.24 B FINANCING CASH FLOW
5.63%
Balance Sheet GSK plc
image
Current Assets 18.6 B
Cash & Short-Term Investments 4.99 B
Receivables 5.9 B
Other Current Assets 7.75 B
Non-Current Assets 40.4 B
Long-Term Investments 2.14 B
PP&E 9.96 B
Other Non-Current Assets 28.3 B
Current Liabilities 21.1 B
Accounts Payable 3.72 B
Short-Term Debt 2.81 B
Other Current Liabilities 14.5 B
Non-Current Liabilities 25.1 B
Long-Term Debt 15.2 B
Other Non-Current Liabilities 9.94 B
EFFICIENCY
Earnings Waterfall GSK plc
image
Revenue 30.3 B
Cost Of Revenue 8.56 B
Gross Profit 21.8 B
Operating Expenses 15 B
Operating Income 6.74 B
Other Expenses 1.82 B
Net Income 4.93 B
RATIOS
71.76% GROSS MARGIN
71.76%
22.24% OPERATING MARGIN
22.24%
16.25% NET MARGIN
16.25%
36.92% ROE
36.92%
8.35% ROA
8.35%
14.49% ROIC
14.49%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis GSK plc
image
Net Income 4.93 B
Depreciation & Amortization 2.29 B
Capital Expenditures -2.34 B
Stock-Based Compensation 307 M
Change in Working Capital -841 M
Others 1.19 B
Free Cash Flow 4.42 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets GSK plc
image
Wall Street analysts predict an average 1-year price target for GSK of $58 , with forecasts ranging from a low of $36 to a high of $85 .
GSK Lowest Price Target Wall Street Target
36 USD -5.38%
GSK Average Price Target Wall Street Target
58 USD 52.45%
GSK Highest Price Target Wall Street Target
85 USD 123.42%
4. DIVIDEND ANALYSIS
0.99% DIVIDEND YIELD
0.393 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership GSK plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
April 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against GSK NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit. globenewswire.com - 1 week ago
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131366&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Shareholders That Lost Money on GSK plc (GSK) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131349&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against GSK plc LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE:GSK) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2020 and August 14, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before April 7, 2025. accessnewswire.com - 1 week ago
Class Action Filed Against GSK plc (GSK) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131269&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
GSK plc Class Action: Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131170&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
GSK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GSK plc Shareholders Have Opportunity to Lead Class Action Lawsuit! NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc ("GSK" or "the Company") (NYSE:GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts ("ADRs") between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"). accessnewswire.com - 1 week ago
GSK plc Class Action: Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. prnewswire.com - 1 week ago
Shareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131115&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131079&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
ROSEN, A LEADING NATIONAL FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK NEW YORK, NY / ACCESS Newswire / February 20, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. accessnewswire.com - 1 week ago
The Gross Law Firm Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline – GSK NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). globenewswire.com - 1 week ago
8. Profile Summary

GSK plc GSK

image
COUNTRY UK
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 77.6 B
Dividend Yield 0.99%
Description GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Contact 980 Great West Road, Brentford, TW8 9GS https://www.gsk.com
IPO Date March 28, 1980
Employees 70212
Officers Ms. Sally Jackson Senior Vice President of Global Communications & Chief Executive Officer Office Ms. Diana Conrad Chief People Officer Mr. Nick Stone SVice President & Head of Investor Relations Ms. Julie Belita Brown A.C.A. Chief Financial Officer & Executive Director Mr. James Ford Senior Vice President & Group General Counsel of Legal & Compliance Ms. Shobie Ramakrishnan Chief Digital & Technology Officer Mr. Tony Wood Chief Scientific Officer and Head of R&D Mr. Philip C. Thomson President of Global Affairs Ms. Emma Natasha Walmsley Chief Executive Officer & Director Mr. David Simon Redfern BSc (Hons), CA President of Corporate Development